| Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection SL Walmsley, A Antela, N Clumeck, D Duiculescu, A Eberhard, ... New England Journal of Medicine 369 (19), 1807-1818, 2013 | 1021 | 2013 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 745 | 2021 |
| Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study A Castagna, F Maggiolo, G Penco, D Wright, A Mills, R Grossberg, ... The Journal of infectious diseases 210 (3), 354-362, 2014 | 425 | 2014 |
| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 … P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ... The Lancet 393 (10167), 143-155, 2019 | 408 | 2019 |
| Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised … J van Lunzen, F Maggiolo, JR Arribas, A Rakhmanova, P Yeni, B Young, ... The Lancet infectious diseases 12 (2), 111-118, 2012 | 378 | 2012 |
| Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors F Maggiolo, L Ravasio, D Ripamonti, G Gregis, G Quinzan, C Arici, ... Clinical infectious diseases 40 (1), 158-163, 2005 | 307 | 2005 |
| One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects M Airoldi, M Zaccarelli, L Bisi, T Bini, A Antinori, C Mussini, F Bai, ... Patient preference and adherence, 115-125, 2010 | 267 | 2010 |
| Whole-genome sequencing reveals host factors underlying critical COVID-19 A Kousathanas, E Pairo-Castineira, K Rawlik, A Stuckey, CA Odhams, ... Nature 607 (7917), 97-103, 2022 | 238 | 2022 |
| Cytomegalovirus coinfection is associated with an increased risk of severe non–AIDS-defining events in a large cohort of HIV-infected patients M Lichtner, P Cicconi, S Vita, A Cozzi-Lepri, M Galli, S Lo Caputo, ... The Journal of infectious diseases 211 (2), 178-186, 2015 | 218 | 2015 |
| Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C E Minola, D Prati, F Suter, F Maggiolo, F Caprioli, A Sonzogni, M Fraquelli, ... Blood, The Journal of the American Society of Hematology 99 (12), 4588-4591, 2002 | 214 | 2002 |
| Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI-or PI-treated patients F Maggiolo, M Airoldi, HD Kleinloog, A Callegaro, V Ravasio, C Arici, ... HIV clinical trials 8 (5), 282-292, 2007 | 193 | 2007 |
| Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study C Fallerini, S Daga, S Mantovani, E Benetti, N Picchiotti, D Francisci, ... elife 10, e67569, 2021 | 179 | 2021 |
| Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial F Maggiolo, D Ripamonti, G Gregis, G Quinzan, A Callegaro, F Suter Aids 18 (3), 439-446, 2004 | 162 | 2004 |
| Efavirenz: a decade of clinical experience in the treatment of HIV F Maggiolo Journal of Antimicrobial Chemotherapy 64 (5), 910-928, 2009 | 154 | 2009 |
| Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 … A Cozzi-Lepri, M Noguera-Julian, F Di Giallonardo, R Schuurman, ... Journal of antimicrobial chemotherapy 70 (3), 930-940, 2015 | 144 | 2015 |
| Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C R D'Ambrosio, L Pasulo, M Puoti, M Vinci, M Schiavini, S Lazzaroni, ... Journal of hepatology 70 (3), 379-387, 2019 | 142 | 2019 |
| Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection … HJ Stellbrink, JR Arribas, JL Stephens, H Albrecht, PE Sax, F Maggiolo, ... The lancet HIV 6 (6), e364-e372, 2019 | 141 | 2019 |
| Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated … C Orrell, DP Hagins, E Belonosova, N Porteiro, S Walmsley, V Falcó, ... The Lancet HIV 4 (12), e536-e546, 2017 | 138 | 2017 |
| Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients M Franco, R Diego, A Claudio, G Giampietro, Q Giampaolo, ... HIV Clinical Trials 3 (5), 371-378, 2002 | 127 | 2002 |
| Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer D Ripamonti, D Cattaneo, F Maggiolo, M Airoldi, L Frigerio, P Bertuletti, ... Aids 21 (18), 2409-2415, 2007 | 116 | 2007 |
